AOD 9604: Modified Growth Hormone Fragment Research

What Is AOD 9604?

AOD 9604 (Advanced Obesity Drug 9604) is a synthetic peptide fragment corresponding to amino acids 177-191 of the human growth hormone (hGH) molecule, with an additional tyrosine residue at the N-terminus. Developed initially at Monash University in Australia, it was designed to isolate the metabolic-regulating properties of growth hormone from its growth-promoting effects.

The rationale behind AOD 9604 is pharmacologically interesting: researchers observed that the full growth hormone molecule influences both growth and metabolic processes through different domains. By synthesizing only the C-terminal fragment responsible for metabolic regulation, the goal was to study lipolytic (fat-metabolizing) activity independent of IGF-1-mediated growth signaling.

Mechanism of Action

Research published in the Journal of Endocrinology has elucidated several proposed mechanisms for AOD 9604's metabolic effects:

Lipolytic Pathway Stimulation

Preclinical studies indicate that AOD 9604 stimulates lipolysis (the breakdown of stored fat) through interaction with beta-3 adrenergic receptors on adipocytes. Unlike full-length growth hormone, this fragment does not appear to activate IGF-1 production, which is associated with cellular proliferation and potential adverse effects in long-term research models.

Lipogenesis Inhibition

Research in Obesity Research journal demonstrated that AOD 9604 inhibits lipogenesis — the metabolic pathway that converts circulating sugars and other substrates into stored fat. This dual action (stimulating fat breakdown while inhibiting fat storage) distinguishes it from single-mechanism compounds.

Cartilage and Bone Research

More recent studies have explored AOD 9604's effects on cartilage repair and bone metabolism. Research published in the Journal of Musculoskeletal and Neuronal Interactions has documented effects on chondrocyte proliferation and proteoglycan synthesis in preclinical models, opening new research avenues beyond metabolic studies.

Key Preclinical Findings

Animal model research conducted at Monash University demonstrated that AOD 9604 reduced adipose tissue mass without affecting food intake, lean body mass, or circulating IGF-1 levels. This selectivity was a primary design objective — metabolic effects without growth-promoting side effects.

Studies in obese animal models showed dose-dependent reductions in body fat over multi-week treatment protocols. Importantly, these studies also monitored for adverse effects commonly associated with growth hormone administration (glucose intolerance, antibody formation) and found none at the doses studied.

Structural Properties

AOD 9604 has the molecular formula C₇₈H₁₂₃N₂₃O₂₃S₂ with a molecular weight of approximately 1,817 Daltons. It is a 16-amino acid peptide stabilized by a disulfide bond between cysteine residues at positions 182 and 189 of the parent hGH sequence.

The peptide is supplied as a lyophilized white powder, soluble in bacteriostatic water. It should be stored at -20°C in lyophilized form and at 2-8°C once reconstituted, with a recommended use window of 21 days post-reconstitution.

Comparison to Full-Length Growth Hormone

The critical distinction between AOD 9604 and hGH lies in receptor specificity. Full-length growth hormone (191 amino acids) activates multiple receptor pathways, including those driving IGF-1 production, cellular growth, and glucose metabolism. AOD 9604 appears to engage only the metabolic-regulating subset of these pathways.

This selectivity makes AOD 9604 a valuable research tool for studying fat metabolism independent of the broader endocrine effects of growth hormone.

AOD 9604 is provided for laboratory research use only. Not for human consumption.

Frequently Asked Questions

What is AOD 9604 derived from?

AOD 9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone, with an added tyrosine at the N-terminus. It was designed to isolate the metabolic-regulating properties of hGH from its growth-promoting effects.

Does AOD 9604 increase IGF-1 levels?

Preclinical research indicates that AOD 9604 does not stimulate IGF-1 production, unlike full-length growth hormone. This is a key distinction, as the fragment appears to engage only metabolic regulatory pathways without activating growth-related signaling.

How is AOD 9604 different from HGH Fragment 176-191?

AOD 9604 and HGH Fragment 176-191 share the same core sequence (amino acids 177-191 of growth hormone), but AOD 9604 includes an additional tyrosine residue at the N-terminus and a stabilizing disulfide bond that may enhance its stability and bioactivity in research settings.